Amivantamab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Amivantamab" in English language version.

refsWebsite

Global rank English rank

18web.archive.org

1^st place

5fda.gov

447^th place

338^th place

5nih.gov

4^th place

3europa.eu

68^th place

117^th place

2globenewswire.com

2,614^th place

1,549^th place

2doi.org

2^nd place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1hres.ca

low place

1prnewswire.com

406^th place

258^th place

1janssen.com

low place

1who.int

195^th place

302^nd place

1handle.net

102^nd place

76^th place

1businesswire.com

615^th place

407^th place

businesswire.com

"Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer" (Press release). Janssen Pharmaceutical Companies. 20 May 2021. Archived from the original on 22 May 2021. Retrieved 23 May 2021 – via Business Wire.

canada.ca

health-products.canada.ca

"Rybrevant Product information". Health Canada. 25 April 2012. Archived from the original on 29 June 2022. Retrieved 29 June 2022.

doi.org

Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. (October 2021). "Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study". Journal of Clinical Oncology. 39 (30): 3391–3402. doi:10.1200/JCO.21.00662. PMC 8791812. PMID 34339292.
Kaplon H, Reichert JM (2021). "Antibodies to watch in 2021". mAbs. 13 (1): 1860476. doi:10.1080/19420862.2020.1860476. PMC 7833761. PMID 33459118.

europa.eu

ema.europa.eu

"Rybrevant EPAR". European Medicines Agency (EMA). 12 October 2021. Archived from the original on 23 April 2022. Retrieved 23 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Rybrevant: Pending EC decision". European Medicines Agency. 15 October 2021. Archived from the original on 15 October 2021. Retrieved 15 October 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Rybrevant Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.

fda.gov

"FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021. This article incorporates text from this source, which is in the public domain.
"FDA grants accelerated approval to amivantamab-vmjw for mNSCLC". U.S. Food and Drug Administration (FDA). 21 May 2021. Archived from the original on 22 May 2021. Retrieved 21 May 2021. This article incorporates text from this source, which is in the public domain.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
"FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications". U.S. Food and Drug Administration (FDA). 1 March 2024. Archived from the original on 9 March 2024. Retrieved 9 March 2024. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshot: Rybrevant". U.S. Food and Drug Administration (FDA). 9 May 2023. Archived from the original on 10 May 2023. Retrieved 9 May 2023. This article incorporates text from this source, which is in the public domain.

globenewswire.com

"Genmab Announces that Janssen has been Granted U.S. FDA" (Press release). Genmab A/S. 21 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021 – via GlobeNewswire.
"Rybrevant (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations" (Press release). Janssen Cilag International NV. 28 June 2024. Archived from the original on 3 July 2024. Retrieved 3 July 2024 – via GlobeNewswire.

handle.net

hdl.handle.net

World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83" (PDF). WHO Drug Information. 34 (1). hdl:10665/339768. Archived (PDF) from the original on 19 April 2021. Retrieved 23 May 2021.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision - Rybrevant". Health Canada. 23 October 2014. Archived from the original on 6 August 2022. Retrieved 6 August 2022.

janssen.com

"Rybrevant (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations". Janssen (Press release). Archived from the original on 3 July 2024. Retrieved 2 July 2024.

nih.gov

ncbi.nlm.nih.gov

Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. (October 2021). "Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study". Journal of Clinical Oncology. 39 (30): 3391–3402. doi:10.1200/JCO.21.00662. PMC 8791812. PMID 34339292.
Kaplon H, Reichert JM (2021). "Antibodies to watch in 2021". mAbs. 13 (1): 1860476. doi:10.1080/19420862.2020.1860476. PMC 7833761. PMID 33459118.

pubmed.ncbi.nlm.nih.gov

Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. (October 2021). "Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study". Journal of Clinical Oncology. 39 (30): 3391–3402. doi:10.1200/JCO.21.00662. PMC 8791812. PMID 34339292.
Kaplon H, Reichert JM (2021). "Antibodies to watch in 2021". mAbs. 13 (1): 1860476. doi:10.1080/19420862.2020.1860476. PMC 7833761. PMID 33459118.

dailymed.nlm.nih.gov

"Rybrevant- amivantamab injection". DailyMed. Janssen Pharmaceutical Companies. Archived from the original on 26 May 2021. Retrieved 25 May 2021.

prnewswire.com

"Rybrevant (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations" (Press release). Janssen Pharmaceutical Companies. 21 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021 – via PR Newswire.

tga.gov.au

"Rybrevant (Janssen-Cilag Pty Ltd)". Therapeutic Goods Administration (TGA). 13 January 2023. Archived from the original on 27 March 2023. Retrieved 18 April 2023.

web.archive.org

"Rybrevant (Janssen-Cilag Pty Ltd)". Therapeutic Goods Administration (TGA). 13 January 2023. Archived from the original on 27 March 2023. Retrieved 18 April 2023.
"Rybrevant Product information". Health Canada. 25 April 2012. Archived from the original on 29 June 2022. Retrieved 29 June 2022.
"Summary Basis of Decision - Rybrevant". Health Canada. 23 October 2014. Archived from the original on 6 August 2022. Retrieved 6 August 2022.
"Rybrevant- amivantamab injection". DailyMed. Janssen Pharmaceutical Companies. Archived from the original on 26 May 2021. Retrieved 25 May 2021.
"FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021. This article incorporates text from this source, which is in the public domain.
"FDA grants accelerated approval to amivantamab-vmjw for mNSCLC". U.S. Food and Drug Administration (FDA). 21 May 2021. Archived from the original on 22 May 2021. Retrieved 21 May 2021. This article incorporates text from this source, which is in the public domain.
"Rybrevant EPAR". European Medicines Agency (EMA). 12 October 2021. Archived from the original on 23 April 2022. Retrieved 23 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Rybrevant (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations" (Press release). Janssen Pharmaceutical Companies. 21 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021 – via PR Newswire.
"Genmab Announces that Janssen has been Granted U.S. FDA" (Press release). Genmab A/S. 21 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021 – via GlobeNewswire.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
"FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications". U.S. Food and Drug Administration (FDA). 1 March 2024. Archived from the original on 9 March 2024. Retrieved 9 March 2024. This article incorporates text from this source, which is in the public domain.
"Rybrevant (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations". Janssen (Press release). Archived from the original on 3 July 2024. Retrieved 2 July 2024.
"Drug Trials Snapshot: Rybrevant". U.S. Food and Drug Administration (FDA). 9 May 2023. Archived from the original on 10 May 2023. Retrieved 9 May 2023. This article incorporates text from this source, which is in the public domain.
"Rybrevant: Pending EC decision". European Medicines Agency. 15 October 2021. Archived from the original on 15 October 2021. Retrieved 15 October 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Rybrevant Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
"Rybrevant (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations" (Press release). Janssen Cilag International NV. 28 June 2024. Archived from the original on 3 July 2024. Retrieved 3 July 2024 – via GlobeNewswire.
World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83" (PDF). WHO Drug Information. 34 (1). hdl:10665/339768. Archived (PDF) from the original on 19 April 2021. Retrieved 23 May 2021.
"Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer" (Press release). Janssen Pharmaceutical Companies. 20 May 2021. Archived from the original on 22 May 2021. Retrieved 23 May 2021 – via Business Wire.

who.int

cdn.who.int

World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83" (PDF). WHO Drug Information. 34 (1). hdl:10665/339768. Archived (PDF) from the original on 19 April 2021. Retrieved 23 May 2021.